Immediate Impact
62 standout
Citing Papers
Polymeric Nanoparticles for Drug Delivery
2024 Standout
Fluorescent Probes for Disease Diagnosis
2024 Standout
Works of Daniel Serin being referenced
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
2013
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
2006
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Daniel Serin | 1229 | 798 | 60 | 293 | 42 | 1.5k | |
| Ingvil Mjaaland | 866 | 803 | 31 | 233 | 43 | 1.6k | |
| R. Largillier | 926 | 518 | 96 | 193 | 47 | 1.5k | |
| Mauro Mansutti | 1030 | 696 | 54 | 176 | 43 | 1.4k | |
| Agnès J. van de Wouw | 1295 | 528 | 77 | 154 | 55 | 1.6k | |
| Thomas J. Saphner | 1273 | 514 | 32 | 165 | 30 | 1.8k | |
| Vernon Harvey | 1241 | 467 | 136 | 303 | 44 | 1.8k | |
| Catharina Wenzel | 966 | 398 | 12 | 214 | 48 | 1.4k | |
| Mariantonietta Colozza | 999 | 466 | 41 | 228 | 36 | 1.4k | |
| Hanna Bandos | 815 | 578 | 17 | 227 | 63 | 1.3k | |
| H. Y. Yap | 921 | 528 | 105 | 93 | 39 | 1.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...